These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32407570)

  • 1. Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.
    Jorge A; McCormick N; Lu N; Zheng Y; Esdaile J; De Vera M; Choi H; Aviña-Zubieta JA
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1219-1223. PubMed ID: 32407570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
    Jorge A; Lu N; Choi H; Esdaile JM; Lacaille D; Avina-Zubieta JA
    Arthritis Care Res (Hoboken); 2023 Apr; 75(4):743-748. PubMed ID: 34941008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus.
    Gupta A; Shields KJ; Manzi S; Wasko MC; Sharma TS
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):828-832. PubMed ID: 33098269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
    Feldman CH; Yazdany J; Guan H; Solomon DH; Costenbader KH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1712-21. PubMed ID: 26097166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study.
    Hoque MR; Lu L; Daftarian N; Esdaile JM; Xie H; Aviña-Zubieta JA
    Arthritis Rheumatol; 2023 Mar; 75(3):475-484. PubMed ID: 36054570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
    Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
    JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine.
    Sakai R; Honda S; Tanaka E; Majima M; Konda N; Takada H; Harigai M
    Lupus; 2020 Nov; 29(13):1712-1718. PubMed ID: 32838624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus.
    Feldman CH; Collins J; Zhang Z; Subramanian SV; Solomon DH; Kawachi I; Costenbader KH
    Semin Arthritis Rheum; 2018 Oct; 48(2):205-213. PubMed ID: 29458974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
    Trefond L; Lhote R; Mathian A; de Chambrun MP; Pha M; Hie M; Miyara M; Papo M; Moyon Q; Taieb D; Saade S; Salem TB; Haroche J; Chasset F; Aubart FC; Zahr N; Amoura Z
    Semin Arthritis Rheum; 2024 Jun; 66():152417. PubMed ID: 38394986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
    Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus.
    Hsu CY; Lin YS; Cheng TT; Syu YJ; Lin MS; Lin HF; Su YJ; Chen YC; Chen JF; Chen TH
    Rheumatology (Oxford); 2018 Oct; 57(10):1743-1751. PubMed ID: 29931367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.
    Schmajuk G; Yazdany J; Trupin L; Yelin E
    Arthritis Care Res (Hoboken); 2010 Mar; 62(3):386-92. PubMed ID: 20391485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
    Hsu CY; Lin YS; Su YJ; Lin HF; Lin MS; Syu YJ; Cheng TT; Yu SF; Chen JF; Chen TH
    Rheumatology (Oxford); 2017 Dec; 56(12):2212-2221. PubMed ID: 29029334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
    Wakiya R; Ueeda K; Shimada H; Nakashima S; Kameda T; Miyatake N; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Clin Rheumatol; 2022 Nov; 41(11):3345-3353. PubMed ID: 35849246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.